Spinnaker Trust Purchases 50 Shares of Danaher Co. (NYSE:DHR)

Spinnaker Trust grew its position in Danaher Co. (NYSE:DHR) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,304 shares of the conglomerate’s stock after acquiring an additional 50 shares during the quarter. Spinnaker Trust’s holdings in Danaher were worth $988,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in DHR. Fort Pitt Capital Group LLC increased its position in shares of Danaher by 3.2% during the 3rd quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after purchasing an additional 7,421 shares during the last quarter. Good Life Advisors LLC bought a new position in shares of Danaher during the 3rd quarter valued at approximately $217,000. ORG Partners LLC increased its position in shares of Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after purchasing an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. increased its position in shares of Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Generate Investment Management Ltd bought a new position in shares of Danaher during the 4th quarter valued at approximately $8,044,000. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 1.5 %

Shares of DHR stock opened at $206.66 on Friday. The stock’s 50-day simple moving average is $230.00 and its 200-day simple moving average is $249.96. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market capitalization of $149.26 billion, a PE ratio of 39.14, a P/E/G ratio of 2.68 and a beta of 0.83. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm earned $2.09 EPS. Equities analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.52%. Danaher’s payout ratio is 20.45%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Scotiabank assumed coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Guggenheim initiated coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Wells Fargo & Company dropped their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, Stifel Nicolaus boosted their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.